Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
| | |

Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab

ByHolly Zink

Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One…

Clinical Trial Participation: Perspectives from Mesothelioma Patients and Caregivers
| |

Clinical Trial Participation: Perspectives from Mesothelioma Patients and Caregivers

ByHolly Zink

Clinical trial participation is a common topic for mesothelioma patients and their caregivers. Treatment options for mesothelioma are increasing. This is a direct result of the number of clinical trials available to patients. Yet, little is known about patients’ and relatives’ feelings about trial participation. A new study provides insight into people’s experiences of clinical trial participation. They also report what factors influence decision-making. Scientists interviewed twelve people, comprising five mesothelioma patients and seven relatives. They identified four themes related to the experience of mesothelioma. First, is the physicality of the disease. Second, the patient’s quality of life. Third, uncertainty and risk are associated with mesothelioma. And fourth, planning for an unpredictable future. A further theme included attitudes on clinical…

First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy
| |

First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy

ByHolly Zink

A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural mesothelioma is an aggressive cancer that affects older adults. Mesothelioma patients often have other comorbidities making real-world treatment decisions challenging. The first was by choice of first-line chemotherapy. The second was the physician’s choice of second-line chemotherapy versus immunotherapy. And the third was by the physician’s choice of use of maintenance therapy. Physician’s Choice of First-Line Chemotherapy Drugs This is the largest real-world study of U.S. patients diagnosed with mesothelioma. Scientists analyzed physicians’ choice of first-line chemotherapy, second-line therapy, and maintenance therapy. In the first-line chemotherapy analysis, there was no significant difference in patient survival. As of this writing, the only…

Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment
| |

Immunotherapeutic and Targeted Approaches to Mesothelioma Treatment

ByHolly Zink

Immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. Malignant pleural mesothelioma is an aggressive disease. Asbestos exposure has led to globally poor outcomes. While mesothelioma is an uncommon disease, its occurrence is increasing worldwide. Immunotherapy drugs have the potential to make chemotherapy more effective for mesothelioma patients. Researchers theorized immunotherapeutic and targeted approaches might make mesothelioma more responsive to chemotherapy. The latest results in Molecular and Clinical Oncology suggest that they were right. The findings could have implications for people around the world with mesothelioma. First- and Second-Line Treatment Options for Mesothelioma Patients affected by mesothelioma have a very severe prognosis. Mesothelioma develops after three to four decades after initial exposure to asbestos. For years, the main…

Precision Medicine Treatment: Gene-Targeting Mesothelioma
| |

Precision Medicine Treatment: Gene-Targeting Mesothelioma

ByHolly Zink

A new precision medicine treatment for mesothelioma comes from scientists in Italy. This form of mesothelioma occurs after asbestos exposure in people with a genetic mutation. The mutation is represented by patients with an inherited cancer syndrome. These patients typically have an even worse prognosis than other mesothelioma patients. But the Italian team came up with a way to target the mutated gene. This form of treatment is called precision medicine. Precision medicine treatment looks at the genetics of a patient to select a treatment that will work best for them. Discovery of a DNA Gene Mutation Malignant pleural mesothelioma is a rare and aggressive cancer caused by exposure to asbestos. Malignant mesothelioma is one of the most aggressive kinds…

Radiation Therapy for Mesothelioma Patients: Value and Timing
| | |

Radiation Therapy for Mesothelioma Patients: Value and Timing

ByHolly Zink

The value and safety of radiation therapy for mesothelioma patients are promising. Oncologists from the Fox Chase Cancer Center released new data on radiotherapy. What are the options for radiation therapy? What is the best timing? Who should receive it? This guide shows the role of radiotherapy in the treatment of mesothelioma. Mesothelioma Radiosensitivity and Treatment Combinations Mesothelioma tumors are radiosensitive. This means they are sensitive to X-rays and radiant energy forms. In other words, mesothelioma tumors are treatable with radiation therapy. The use of a multi-modality treatment has also shown potential for mesothelioma patients. A tri-modality treatment uses three different treatment types. The combination of surgery, chemotherapy, and radiotherapy is most common. Understanding Timing and Adverse Effects There are…

Asbestos Exposure in Construction Workers Leads to Mesothelioma
| | |

Asbestos Exposure in Construction Workers Leads to Mesothelioma

ByHolly Zink

Asbestos exposure in construction workers remains a particular concern. Malignant mesothelioma is a rare cancer with a global incidence. Italy is among the countries with the highest values of mesothelioma. Mesothelioma is associated with exposures to asbestos fibers and other asbestiform fibers. Asbestos exposure in construction workers remains a particular concern. A new study describes the characteristics of Italian malignant mesothelioma cases among construction workers. Scientists analyzed 31,572 cases with definite asbestos exposure in the period from 1993 to 2018. Connecting Asbestos Exposure and Mesothelioma in Construction Workers The relation between asbestos use and the historical trend of mesothelioma is clear. Italian scientists assessed asbestos exposure in 78.2% of the mesothelioma cases. This accounts for 24,864 of the patients studied….

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma
| | |

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma

ByHolly Zink

Nivolumab + ipilimumab continues to provide a long-term survival benefit in malignant pleural mesothelioma. A new report shows a 3-year follow-up in the CheckMate Clinical Trial. Long-term clinical benefits remained the same for all patient groups. Background on the Nivolumab + Ipilimumab Treatment Two years ago, the FDA approved the combination of nivolumab + ipilimumab. It is the first-line treatment for patients with metastatic non-small cell lung cancer. The CHECKMATE randomized multi-part trial investigated the effectiveness. The trial showed a significant improvement in patient survival. Today, this treatment combination improves patient survival rates over chemotherapy. Mesothelioma patients showed an improved survival using this line of treatment. A new report from the Annals of Oncology describes updated data with at least…

Top Three Factors Predicting Mesothelioma Survival are Age, Histological Type, and Surgery Status
| | | |

Top Three Factors Predicting Mesothelioma Survival are Age, Histological Type, and Surgery Status

ByHolly Zink

Malignant pleural mesothelioma is a rare and aggressive malignancy with a dismal prognosis. A new study is predicting mesothelioma survival among male and female patients in the United States. Identifying factors “associated with mesothelioma mortality is important research given the poor prognosis” according to Dr. Bian Liu from the a Icahn School of Medicine at Mount Sinai in New York. A new study applied a machine-learning algorithm to 12,210 patients to predict survival. The top three factors were age, histological type, and cancer-directed surgery status. Analyzing Over 12,000 Mesothelioma Patients Scientists from the New York State Department of Health included 12,210 mesothelioma patients. They involved only malignant pleural mesothelioma patients. They excluded cases with unknown diagnostic confirmation and unknown survival…

Two New Diagnostic Tissue Biomarkers Discovered for Mesothelioma
| | |

Two New Diagnostic Tissue Biomarkers Discovered for Mesothelioma

ByHolly Zink

Scientists have now identified two new diagnostic tissue biomarkers for malignant pleural mesothelioma. Doctors identify mesothelioma using diagnostic tissue biomarkers. This is called immunohistochemistry. The use of immunohistochemistry improves the accuracy of mesothelioma diagnosis in clinical practice. Yet, new methods for discovering diagnostic markers are still needed. Following a Reverse Approach in a Rare Case Mesothelioma is usually diagnosed after a person experiencing symptoms goes to a doctor. One thing a doctor may do is perform a tissue biopsy. The doctor will remove a part of the tissue (suspected mesothelioma) for examination. Most tissue biopsies are done with a needle and then examined in a laboratory. The lab will look for specific biomarkers to find out if the tissue contains…